About
Technology
Issues
FAQ
Links
Official Page
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.